Abo-Salem Elsayed, Becker Richard
Division of Cardiovascular Health and Disease, University of Cincinnati College of Medicine, University of Cincinnati, 231 Albert Sabin Way, Room 3461 MSB, PO Box 670542, Cincinnati, OH, 45267-0542, USA,
J Thromb Thrombolysis. 2014 Apr;37(3):372-9. doi: 10.1007/s11239-014-1060-y.
Vitamin K antagonists have been the only available oral anticoagulant therapy for decades until the recent introduction of novel (new) oral anticoagulants. This breakthrough provides patients with alternative treatment choices that have predictable pharmacokinetics and do not require routine coagulation monitoring. Though more convenient from patient perspective, these drugs have distinct pharmacological properties that are particularly important to recognize when transitioning anticoagulant therapies. The following review focuses on transitioning to and from the novel oral anticoagulants, employing a practical pharmacokinetic- and pharmacodynamic-based approach.
几十年来，维生素K拮抗剂一直是唯一可用的口服抗凝治疗药物，直到最近新型口服抗凝药的出现。这一突破为患者提供了具有可预测药代动力学且无需常规凝血监测的替代治疗选择。尽管从患者角度来看更方便，但这些药物具有独特的药理特性，在抗凝治疗转换时认识到这一点尤为重要。以下综述重点关注新型口服抗凝药的转换，采用基于药代动力学和药效学的实用方法。
